Ferroptosis: the emerging player in remodeling triple-negative breast cancer
J Li, D He, S Li, J Xiao, Z Zhu - Frontiers in Immunology, 2023 - frontiersin.org
Triple-negative breast cancer (TNBC) is a highly heterogeneous breast tumor type that is
highly malignant, invasive, and highly recurrent. Ferroptosis is a unique mode of …
highly malignant, invasive, and highly recurrent. Ferroptosis is a unique mode of …
PROTACs: A novel strategy for cancer drug discovery and development
Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …
[HTML][HTML] Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype
S Asemota, W Effah, KL Young, J Holt, L Cripe… - Cell reports, 2023 - cell.com
Triple-negative breast cancer (TNBC) is an aggressive subtype with no targeted
therapeutics. The luminal androgen receptor (LAR) subtype constitutes 15% of TNBC and is …
therapeutics. The luminal androgen receptor (LAR) subtype constitutes 15% of TNBC and is …
Naturally sourced amphiphilic peptides as paclitaxel vehicles for breast cancer treatment
R Chen, E Liu, Y Fang, N Gao, M Zhang, X Zhang… - Biomaterials …, 2024 - Elsevier
The marketed paclitaxel (PTX) formulation Taxol relies on the application of Cremophor EL
as a solubilizer. The major drawback of Taxol is its hypersensitivity reactions and a …
as a solubilizer. The major drawback of Taxol is its hypersensitivity reactions and a …
Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements
L Yao, J Chen, W Ma - Frontiers in Oncology, 2023 - frontiersin.org
Breast cancer is a heterogeneous disease characterized by distinct molecular subtypes,
varied prognoses, and differential treatment responses. Understanding the molecular …
varied prognoses, and differential treatment responses. Understanding the molecular …
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer
RQ Li, L Yan, L Zhang, HX Ma, HW Wang, P Bu… - Scientific Reports, 2024 - nature.com
Triple-negative breast cancer (TNBC) has high heterogeneity, poor prognosis, and limited
treatment success. Recently, an immunohistochemistry-based surrogate classification for the …
treatment success. Recently, an immunohistochemistry-based surrogate classification for the …
Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
X Li, L Zhang, S Hu, D Liu, B Hu, J Ran… - Clinical …, 2024 - Wiley Online Library
Sacituzumab govitecan is widely used for the treatment of breast cancer and urothelial
carcinoma, but available information regarding adverse events (AEs) is limited. We aim to …
carcinoma, but available information regarding adverse events (AEs) is limited. We aim to …
A Novel CRISPR/Cas9‐Encapsulated Biomimetic Manganese Sulfide Nanourchins for Targeted Magnetic Resonance Contrast Enhancement and Self‐Enhanced …
H Liu, M Mu, Y Hou, Y Gong, C Wang… - Advanced Functional …, 2024 - Wiley Online Library
CRISPR/Cas9 gene editing systems are widely studied in cancer therapy, however, it is still
challenging to improve the gene editing efficiency and enhance the anticancer efficacy …
challenging to improve the gene editing efficiency and enhance the anticancer efficacy …
VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating …
RS Thankan, E Thomas, P Purushottamachar… - Frontiers in …, 2023 - frontiersin.org
Triple-negative breast cancer (TNBC) and its recently identified subtype, quadruple negative
breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer …
breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer …
Racial and socioeconomic disparities in triple-negative breast cancer treatment
Introduction Triple-negative breast cancer (TNBC) continues to be a significant concern,
especially among minority populations, where treatment disparities are notably pronounced …
especially among minority populations, where treatment disparities are notably pronounced …